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Effect of chronically increased complement receptors on immune
complex nephritis. Experimental studies in humans and other primates
have shown that the erythrocyte (E) complement receptor Type 1
(CR1), which is unique to the primate, plays an important role in
clearing immune complexes (IC) from the circulation by binding C3b/
C4b opsonized immune complexes and carrying the IC to liver and
spleen for disposal. The results of these acute experiments suggest that
increasing E-CR1 levels chronically should protect against IC-mediated
glomerulonephritis (IC-GN) induced by chronic formation of IC in the
circulation. In the present study this hypothesis was tested in the
cynomolgus monkey (CYN). IC-GN was induced by daily bolus intra-
venous infusion of BGG into immunized CYN for 8, 10, or 14 weeks.
Prior to and during the daily bolus infusions of BGG, sustained
differences in E-CR1 levels were achieved between the experimental
group (increased E-CR1 levels) and the control group (maintained or
decreased E-CR1 levels), by one of two methods: (1) Twice weekly
exchange transfusion. The CYN donors were blood type compatible
with the recipients and had either constitutive high E-CRI expression
(3,000 to 5,000 CR1/E) or constitutive low E-CR1 expression (< 100
CRIE). The recipients of the exchange transfusions (N = 2) had
constitutive mid-level E-CR1 expression. (2) Weekly phlebotomy (PL)
or sham PL. CYN with mid-level E-CR1 expression were randomly
assigned to receive weekly either PL (causing increased B-CR I expres-
sion by stimulating erythropoiesis) (N = 8) or sham PL (which has no
effect on E-CR1 expression (N = 9). We found that the exchange
transfusion model produced large differences between the CYN in
CR1/E (mean 910 in the CYN exchanged with high E-CRI donors vs.
210 in the CYN exchanged with the low E-CR1 donors) but was labor
intensive. The PL/sham PL model also induced large and sustained
differences in CRIIE between the PL group (1150 160 CR1/B) and the
sham PL group (530 80 CRI/E), and was relatively easy to perform.
Deaths due to respiratory failure during BGG infusion occurred in the
first week of daily BGG infusion in three CYN randomized to the Sham
PL. These CYN are not included in the final analysis. The primary
outcome variable was a blinded morphometric evaluation of glomerular
electron dense deposits, expressed as the percent of a given glomerular
component occupied by deposit, in the biopsy performed at the
termination of the GN-induction protocol. The renal biopsies done prior
to administration of BGG show no glomerular electron dense deposits.
The terminal renal biopsy results are as follows: in the experimental
group (raised E-CR1 levels) versus the control group (decreased or
maintained E-CRI levels) the glomerular capillary wall electron depos-
its were 3.2 1.5% versus 9.8 3.8% (P = 0.15), and the mesangial
deposits were 14.3 2.2 versus 21.5 5.2%, (P = 0.34). Urine
protein/urine creatinine ratio measured in the terminal urine samples
was 0.7 0.2 in the experimental group and 2.3 1.1 in the control
Received for publication June 9, 1993
and in revised form August 25, 1993
Accepted for publication August 26, 1993
© 1994 by the International Society of Nephrology
group (P = 0.22). Antibody levels, total BGG dose, and serum
creatinine levels were not significantly different between the control and
experimental groups. We conclude that increasing E-CR1 levels chron-
ically does not provide statistically significant protection against gb-
merular accumulation of immune deposits or proteinuria in this bolus
model of IC-GN.
E-CR1, which is unique to the primate, is expressed in
relatively low densities on erythrocytes compared to leuko-
cytes. In humans, the approximate mean number of CR1/cell is:
erythrocytes 500, neutrophils 20,000, B-lymphocytes 21,000
and monocytes 30,000 [1, 2]. However, because there are far
more erythrocytes than leukocytes in the circulation, in pri-
mates over 85% of the CR1 in the circulation are expressed on
erythrocytes [1, 2]. When IC are infused into the circulation or
allowed to form acutely in the circulation passively or actively,
a large fraction of the immune complexes becomes bound to
circulating erythrocytes [1, 2]. The mechanism of binding of IC
to erythrocytes is the opsonization of the IC by C3b/C4b with
subsequent binding to CR1. The IC in the circulation bind
preferentially to E-CR1 because, compared to CR1 on other
circulating cells, the CR1 on erythrocytes are arranged in fixed
clusters which permit multipoint binding of C3b/C4b opsonized
IC [3, 4].
Acute studies in humans and nonhuman primates [1, 2, 5]
have shown that IC bound to erythrocyte have delayed clear-
ance from the circulation because the erythrocyte-bound IC are
removed from the circulation primarily by transfer of the IC
from the erythrocyte to the mononuclear phagocytic cells of
liver and spleen [1, 2, 5]. Studies in the nonhuman primate have
shown that IC bound to erythrocytes are prevented from
depositing in vulnerable organs such as the kidney. Instead, the
IC bound to erythrocytes are primarily taken up by liver and
spleen, as the Fc regions of the IC bound to E-CR1, engage the
Fc receptors of the phagocytic cells of liver and spleen [1, 2, 5].
The erythrocyte then breaks free from the IC and returns to the
circulation apparently able, once again, to participate in what
we have termed the "erythrocyte-IC clearing mechanism" [1,
2, 6].
Erythrocyte CR1 levels are decreased in IC-mediated dis-
eases, probably as a result of damage to the E-CRI as they
interact with IC in the circulation [7, 8] and as the IC are
removed from E-CR1 as the erythrocytes enter liver or spleen
493
494 Hebert et a!: Erythrocyte CR1 and immune complex glomerulonephritis
[9]. It has been suggested that the low E-CR1 levels seen in
IC-mediated diseases may be an exacerbating factor because,
for any given load of circulating IC, more of the circulating IC
may deposit in vulnerable organs such as the kidney [1, 2, 5].
The efficiency of the E-CR1 system can also be diminished
when complement levels are low, thereby impairing the op-
sonization of circulating IC by C3b/C4b. This may be one of the
reasons for the increased incidence of IC-mediated diseases in
patients with complement component deficiencies or deficien-
cies of the regulators of complement that result in deficient C3b
generation [10].
On the basis of the above evidence it has been suggested that
the E-CR1 system may be an important protective mechanism
against IC-mediated diseases in the primate.
Nonprimates also have CR1 on circulating cells; however, in
nonprimates, CR! is expressed on platelets [5] as well as
circulating leukocytes. In nonprimates, the binding of IC to
platelets results in the clearance of the IC and platelets from the
circulation [1, 5]. In vitro studies have shown that complement-
mediated binding of IC to platelets causes the platelets to
aggregate irreversibly [5]. This would seem to be a biological
disadvantage because platelet aggregation is generally followed
by release of inflammatory molecules [1, 5]. By contrast, in the
primate the erythrocyte appears to act as an inert shuttle to
transfer IC from the circulation to the liver and spleen for safe
disposal, as discussed above. Thus, there are multiple lines of
evidence suggesting that the erythrocyte-IC clearing mecha-
nism of the primate provides protection against IC-mediated
disease. However, this hypothesis has not been critically
tested.
The present study was undertaken to test the protective role
of the E-CR! system by using an exchange transfusion model or
a phlebotomy/sham phlebotomy model for the E-CR1 interven-
tion. The IC-GN was induced by daily bolus infusion of antigen.
The histologic characteristics of this model, which have been
described previously, are that of a proliferative GN mainly
involving the mesangium. Immunofluorescent microscopy dem-
onstrates heavy deposition of IgG and C3 in the mesangium and
glomerular capillary wall. Electron microscopy demonstrates
numerous electron dense deposits in the mesangium and in
relation to the glomerular capillary wall [11, 12].
The present studies show a trend for decreased accumulation
of IC in glomeruli and less proteinuria, in the CYN with
increased E-CR1, but those trends did not achieve statistical
significance. However, as discussed herein, the bolus model of
IC-GN may not be a suitable test of the putative protective role
of the E-CR1 system in IC-GN.
Methods
Cynomolgus monkeys (N = 19) were studied (10 males and 9
females). All animals were purchased from the Charles River
Primate Center (Houston, Texas, USA). Prior to entering our
primate colony they were observed for four weeks in quarantine
where they were found to be normal on physical exam, to be
free of tuberculosis, and to have normal values on a compre-
hensive panel of clinical tests including urinalysis. They were
then transferred to our primate colony for study. The diet
consisted of monkey chow, fresh fruit, and water ad libitum.
The animals were evaluated approximately weekly by a veter-
inarian and were weighed weekly. To collect fresh urine sam-
pies, the collection pan at the bottom of the cage was cleaned
and all urine passed over the subsequent hour was examined.
Overnight urine samples were collected in the same fashion.
Procedures for handling the nonhuman primates
For routine procedures (drawing blood by venipuncture,
injecting antigen intravenously, physical examination, measur-
ing body wt) the CYN were sedated with Ketamine 6 mg/kg
given intramuscularly. For the performance of the closed nee-
dle biopsy of the kidney, the CYN were anesthetized more
deeply by repeating the Ketamine dose about 20 minutes after
the initial dose.
Renal biopsy technique
Closed needle biopsy of the kidney was performed as previ-
ously described [11]. In brief, the CYN under Ketamine anes-
thesia were placed in the prone position. The kidneys were
localized by palpation and one was selected for biopsy. A 4-inch
Trucut biopsy needle was used to obtain two cores from the
lower pole or mid region of the kidney. The samples were
examined by dissecting microscope to assess for the presence
of glomeruli. Whenever possible, the biopsy sites in a given
animal were alternated between the two kidneys.
Immunization protocol
As previously described [11, 12], BOG (Calbiochem, San
Diego, California, USA) was emulsified in Freund's complete
adjuvant and injected intramuscularly, 1 mg/kg body weight, in
the hind leg of the animal. At two weeks and four weeks after
the primary immunization, a BGG boost (1 mg/kg in incomplete
Freund' s adjuvant) was injected intramuscularly.
E-CRI interventions
Two different protocols were used to induce a difference in
E-CR1 levels between the experimental group (the CYN with
increased E-CR1 levels) and the control group (the CYN with
maintained or decreased E-CR1 levels). The methods used are
as follows:
Exchange transfusion protocol. Two CYN which constitu-
tively expressed medium E-CR1 levels (300 to 1,000 CR1/E)
were randomly assigned to receive blood type-compatible twice
weekly erythrocyte exchange transfusions from donors that
either constitutively expressed high E-CR1 levels (4,000 to
6,000 CRI/E) or low E-CR1 levels (< 100 CR1/E). As discussed
previously, constitutive E-CR1 expression appears to be deter-
mined by codominant alleles which encode for either high or
low E-CRI expression Ill].
The exchange transfusion consisted of removing 15% of the
blood volume (assumed to be 7% of body wt) into heparin (10
MImI) from the donor using an intravenous catheter. The cells
were washed twice in normal saline, buffy coat cells removed,
and resuspended at a hematocrit of approximately 50% in
preparation for transfusion into the recipient. The recipient was
prepared by removing 15% of blood volume in the same manner
as that used in the donor. However, in the recipient, after
centrifugation of the blood, the plasma and leukocytes were
returned to the recipient and the erythrocytes were discarded.
At this point the recipient was transfused with the donor
erythrocytes. The above process was repeated to achieve
approximately a 30% exchange transfusion. The exchange
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transfusions were begun just prior to the start of the GN-
induction protocol (the first day of the daily i.v. infusions of
BGG), and were well-tolerated.
FL/sham PL protocol. This method to achieve a difference in
E-CR1 expression between an experimental and control group
has been described previously [13]. In brief, CYN were ran-
domly assigned to receive PL or sham PL. PL consisted of
stepwise removal of 30% of the CYN's erythrocyte volume into
heparin 5 U/mi of blood. Intravenous saline was given to
provide hemodynamic stability. The blood removed by phle-
botomy was centrifuged. The erythrocytes were discarded. The
leukocyte and plasma were removed and returned to the CYN.
To replace the iron lost in the discarded erythrocytes, the CYN
was infused intravenously with an appropriate dose of iron
dextran [13]. Sham PL was performed in the same way as PL,
except that all of the blood components were returned to the
CYN. PL/sham PL was well-tolerated by the CYN.
The first PL/sham PL was performed on the day of immuni-
zation to BGG. The GN-induction protocol was not begun until
the CYN had been subjected to four weekly PL/sham PL. Four
weekly PL were needed to achieve peak stimulation of eryth-
ropoiesis and, therefore, peak expression of CR! on erythro-
cytes [13]. The E-CR! levels in the CYN subjected to Sham PL
did not change.
GN-induction protocol
GN was established in each CYN by daily (Monday through
Friday) intravenous infusion of BOG for 8, 10 or 14 weeks.
BOG was administered as follows: a "full" dose of BGG was
that amount of BGG which would consume all of the precipi-
tating antibody present in the intravascular volume [1!]. A
"partial" dose of BGG was 5 mg/kg of CYN body weight. On
Monday and Tuesday of the first two weeks of the study, a
"partial" dose of BOG (5 mg/kg) was given. Thereafter, only
the Monday dose of BGG was a partial dose (5 mg/kg). All other
daily doses of BGG were "full" doses.
The use of a partial dose of BGG on Monday/Tuesday is a
modification of the protocol for GN induction in the CYN which
we described previously [1!, 12]. The partial dose of BOG on
Monday/Tuesday was used because it greatly reduced the
respiratory distress seen when a full dose of BGG was given on
Monday/Tuesday. As discussed previously, the CYN are vul-
nerable to respiratory distress during BGG infusion especially
on Mondays and Tuesdays because the CYN do not receive
BGG on Saturdays or Sundays during the GN-induction proto-
col. As a consequence, over the weekend, antibody levels rise
from nadir levels on Fridays to zenith antibody levels on
Mondays [1!]. If a full dose of BGG is given on Mondays,
severe respiratory distress, and even death, results presumably
from deposition of large amounts of IC in the lungs [1!]. In the
present study, three CYN randomized to sham PL died during
BGG infusion. Alt of the deaths occurred during the first week
of the ON-induction protocol when a full dose of BGG was
given on a Monday or Tuesday. After these deaths, which
occurred in the first group of CYN studied, the protocol was
revised so that only a partial dose of BOG was given on
Mondays/Tuesdays, as described above. The three CYN that
died during BOG infusion are not included in the final results.
Schedule of tests before and during the GN-induction
protocol
Each Monday and Thursday the following tests were per-
formed: hematocrit, mean CR1/E, quantitative precipitins for
BGG in CYN serum, and blood pressure (taken by auscultation
using a pediatric cuff) [11]. Each Monday body weight and
serum creatinine were measured. Every other Monday urine
protein (Coomassie blue method) and urine creatinine were
measured. Renal biopsies were performed prior to immumza-
tion to BGG, four weeks after the start of daily BGG infusion,
and at the termination of the study (8, 10, or 14 weeks of daily
BGG infusion). All testing was done before the CYN received
that day's dose of BGG.
Histologic and morphometric techniques
All renal biopsy specimens were coded and read without
knowledge of the clinical status or group assignment of the
CYN. Routine and quantitative electron microscopy studies
were performed as previously described using osmic acid fixed
tissues analyzed on a Gatan video monitor attached to a Hitachi
600 standard transmission electron microscope [11, 12]. In each
CYN, three or four glomeruli were randomly chosen and
analyzed using point counting techniques as previously de-
scribed [11, 12]. In brief, the glomeruli were analyzed by
histomorphometric techniques as follows.
(1) Glomerular components. A standard point counting tech-
nique [9] was used to determine the relative volumes of the
various glomerular components for each biopsy sample. A
transparent grid containing 40 equally spaced points was at-
tached to the video screen. The identity of the glomerular
component under each point was recorded. Randomly selected
areas of each glomerulus were viewed at 53,000 magnification to
provide at least 800 points per glomerulus. The fractional
volumes of mesangial cell, mesangial matrix, and glomerular
basement membrane (GBM) were calculated for each biopsy.
(2) GBM deposits. Random GBM regions encountered during
the glomerular component determination were viewed at 41,000
magnification and the GBM length measured on the video
monitor. The extent of lamina rara interna (LRI), lamina densa
(LD) and lamina rara extema (LRE) electron dense deposits
was also directly measured on the screen and the percent of
LRI, LD and LRE involved with electron dense deposits was
calculated.
(3) Mesangial deposits. Random mesangial matrix areas
encountered during the glomerular component determination
were viewed at 41,000 magnification. The number of points of
the 40-point transparency grid that fell on mesangial deposits
and the number of points that fell on mesangial matrix were
determined. The percent of mesangial matrix with deposits was
then calculated for each glomerulus and averaged for each
biopsy.
Analytical techniques
BGG was labeled with 1251 as previously described [1!].
Erythrocyte CR! levels were determined as previously de-
scribed [11]. In brief, a mouse monoclonal antibody to human
CR! (provided by Dr. Nancy Hogg) was labeled with 125! to
enumerate CR1/E using a saturating dose of the monoclonal
antibody and a single-point binding assay. Nonspecific binding
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Identifier Sex
Weight
kg
Initial serum
creatinine
mg/dl"
Initial
Upr/Ucr'
Wic F 2.9 0.5 0.25
Ca" F 2.9 0.8 0.30
El" F 2.3 0.7 0.00
Ye" F 2.5 0.6 0.56
Nod M 5.2 0.8 0.22
01d M 4.8 0.7 0.16
Pad M 5.0 0.7 0.13
Ir" F 4.2 0.6 0.21
To" M 6.4 0.9 0.22
X SE 4.0 0.5 0.7 0.3 0.23 0.05
Une F 3.2 0.5 0,19
Da F 2,4 0.6 0.42
Lil M 4.4 1.0 0.09
Ma M 6.1 0.9 0.09
Du M 3.8 0.7 0.13
Le1 M 4.9 0.8 0.20
Wi1 M 5.0 0.7 0.20
X SE 4.3 0.5 0.7 0.8 0.19 0.04
Serum creatinine level
b Ratio of urine protein and urine creatinine concentration, both in
mg/dI
CYN assigned to have E-CR1 increased by exchange transfusion
d CYN assigned to have E-CRI increased by phlebotomy
CYN assigned to have E-CR1 decreased by exchange transfusion
CYN assigned to have E-CR1 maintained by sham FL
was measured by '251-El 1 binding to sheep erythrocytes. Pre-
cipitating antibody levels to BGG were determined as previ-
ously described using serially diluted zI BGG and one-half
diluted serum in a constant volume [11]. The equivalence point
was taken as the inflection point of the antigen excess portion of
the quantitative precipitin curve. All other assays were per-
formed using standard techniques in the clinical laboratories of
The Ohio State University Hospitals.
Statistical methods
Differences between mean values were evaluated for statis-
tical significance using the Wilcoxon rank sum test. This test
was used, rather than the t-test, because both the glomerular
deposit percentages and the urinary protein/creatinine ratios
violated the normal distribution and equal variance assumptions
of the t-test. All tests were two-tailed. Mean values are shown
1 standard error.
Results
Table 1 shows the baseline clinical characteristics of the CYN
which were entered into this study and completed the entire
protocol. As can be seen, at baseline the group assigned to the
intervention to raise E-CR1 levels was comparable to those
assigned to the group to decrease or maintain E-CR1 levels.
Effects of the E-CR1 interventions on E-CRI levels
FL/sham PL protocol. Figure 1 shows the serial changes in
the mean CR1/E in the CYN randomized to the PL or the sham
PL groups. As can be seen, PL resulted in large and sustained
increases in E-CR1 expression, because young erythrocytes
express many more CR1/E than mature erythrocytes [13]. The
increase in E-CR1 expression induced by PL was sustained
even after the start of the GN-induction protocol. By contrast,
the CYN subjected to sham PL maintained E-CR1 levels.
Figure 2 shows the serial changes in hematocrit in the CYN
randomized to the PL versus the sham PL groups before and
during the GN-induction protocol. As can be seen, the hemat-
ocrit levels, which were measured prior to each exchange
transfusion were well-maintained and were not significantly
different from the baseline hematocrit levels nor from the
hematocnt levels measured in the CYN in the sham PL group.
Thus, within one week's time, the CYN in the PL group
replaced virtually all of the erythrocytes removed by the
phlebotomy. Thus, at any given time, approximately one-third
of the erythrocytes of the CYN in the PL group were less than
one week old.
Table 1. Clinical characteristics of the CYN prior to start of the GN-
induction protocol
w
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Sham PL
Start
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I
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Time, weeks
Fig. 1. Serial changes in mean CRJIE before and during the GN-
induction protocol in the CYN subjected to FL (S) versus CYN
subjected to sham PL (0). At all timepoints after baseline, mean CR1/E
is significantly higher in the PL group compared to the sham PL group
(P < 0.02).
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Fig. 2. Serial changes in hematocrit in CYN in the PL group (S) versus
the sham PL group (0) before and during the GN-induction protocol.
There are no significant differences in hematocrit between the groups,
after the start of the GN-induction protocol.
Hebert et a!: Erythrocyte CR1 and immune complex glomerulonephritis 497
Table 2. Antibody responses to BGG in the CYN with increased
CRIIEa or with no increase in CR1/Eb
Precipitating antibody to BGGC
Prior to GN During GN
iflductiofld inductione
Increased CRI/E
PLgroup 145 30 131 26
Exchange transfusion CYN 256 40
No increased CR1/E
Sham PL group 102 28 125 26
Exchange transfusion CYN 128 33
a CYN subjected to PL or to exchange transfusion with high E-CRI
donors
b CYN subjected to sham PL or to exchange transfusion with low
E-CR1 donors
Micrograms 125! BGG precipitated per ml of plasma, at antigen-
antibody equivalenced Antibody levels measured 4 weeks after immunization to BOG but
before daily intravenous infusion of BGG. In the CYN in the PL/sham
PL group the CYN had been exposed to 4 weekly PL or sham PL
eThe average level of precipitating antibody to BGG measured
weekly (each Monday) during the GN-induction protocolP = NS compared to the sham PL group
P = NS compared to the sham PL group
Exchange transfusion protocol. The CYN assigned to the
exchange transfusion protocol that involved the high E-CR1
donors (N = 2 donors) experienced an increase in E-CR1 level
after each exchange transfusion. The mean CR1/B in the
recipient, measured immediately after completing the exchange
transfusion, was usually doubled. However, the increases in
CR1IE following exchange transfusions were not sustained. The
increases in CR1/B observed after the Monday exchange trans-
fusion were largely dissipated by the time of the exchange
transfusion done each Thursday.
In the CYN assigned to the exchange transfusion protocol
that involved the low CR1/E donors (N = 2 donors), E-CR1
levels were approximately halved immediately after each ex-
change transfusion. However, the nadir levels of CR1/E mea-
sured after the Monday exchange transfusion were largely
dissipated by the time of the Thursday exchange transfusion.
The failure of exchange transfusion to induce prolonged
changes in mean CR1/B may have resulted from shortened
survival of the transfused erythrocytes, compared to autolo-
gous erythrocytes.
Other effects of the E-CRJ interventions
White blood cells counts, differential counts, and platelet
counts were measured at four-week intervals in each of the
CYN. No differences were observed between the groups (data
not shown). It has been suggested that B-CR! levels may
influence immune response through an effect on processing of
IC [1, 2]. Thus, it was of interest to examine the antibody
responses in these studies. Table 2 shows the antibody re-
sponses to immunization with BGG in the PL group compared
to the sham PL group prior to the GN-induction protocol. If
increased B-CR! levels influence antibody responses, a differ-
ence in antibody responses between the PL and sham PL
groups should have been seen after four weeks in the PL/sham
PL protocol, because by four weeks of weekly PL/sham PL,
significant differences in CR1/B are seen (Fig. 1). However, as
can be seen, there were no significant differences between the
PL and sham PL groups in the initial antibody responses, or in
the antibody levels maintained during ON induction (Table 2).
The antibody responses in the CYN subjected to exchange
transfusion (Table 2) are also of interest because, initially, high
antibody levels were observed in both CYN. However, in the
weeks following the initiation of exchange transfusion, antibody
levels decreased progressively. In our previous studies of CYN
chronically infused with BOG, we did not observe a pattern of
progressively decreasing antibody levels during daily i.v. infu-
sion of BGG. Rather, BGG antibody levels were well-main-
tained [11, 12, 14]. We suggest that the exchange transfusion
protocol resulted in suppression of immune responses to BGG.
Effects of the E-CRI intervention on the induction of GN
As can be seen from Table 3, the CYN studied under the
exchange transfusion protocol were subjected to the GN-
induction protocol for 14 weeks. The CYN studied under the
PL/sham PL protocol were subjected to the GN-induction
protocol for eight or 10 weeks. The E-CR1 interventions were
effective in achieving large and significant differences in CR1/B
between the control group (sham PL, or exchange transfusion
with low E-CR1 donors), and the experimental group (PL
group, or exchange transfusion with high E-CR1 donor) (P <
0.005).
The primary outcome measure of this study was the extent of
glomerular electron dense deposits measured morphometncally
[11, 12] in the renal biopsy performed at the termination of the
GN-induction protocol. Each CYN also underwent renal biopsy
prior to immunization to BGG. No significant glomerular elec-
tron dense deposits were observed in these biopsies. Thus, the
glomerular electron dense deposits measured on the terminal
renal biopsy represent deposits which accumulated during the
GN-induction protocol. We have previously shown that these
glomerular deposits contain IgG and C3 and, thus, represent
immune complexes [11, 12]. The results of the morphometric
analysis of these glomerular immune deposits are shown in
Table 3.
The morphometric analysis shows that there was a trend for
fewer glomerular immune deposits in the subepithelial space (P
= 0.22), capillary wall (P = 0.15), and mesangium (P = 0.34).
However, none of these differences achieved statistical signif-
icance. As can also be seen from Table 3, the antibody
responses between the control and experimental groups were
comparable, as were the average BGG doses.
Proteinuria was numerically less in the experimental group
compared to the control group; however, these differences did
not achieve statistical significance (P 0.22). Serum creatinine
levels did not change significantly from baseline (Table 1) in the
control or experimental group.
Discussion
The present study shows that, in this model of IC-GN, a
sustained increase in E-CR1 expression does not provide sta-
tistically significant protection against accumulation of glomer-
ular immune deposits or proteinuria. The increase in E-CRI
expression achieved in these studies should approximately
double the ability of E-CR! to bind IC [1, 2]. Thus, these
observations suggest that the B-CR! system does not provide
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important protection against IC-GN, as has been previously
hypothesized [1, 2, 5, 15, 16].
It is possible, however, that increased E-CR1 levels can
protect against IC-GN, but the bolus model of IC-GN obscures
that effect because bolus infusion of antigen overwhelms the
ability of the E-CR1 system to bind the IC acutely that form in
the circulation. That is, the efficiency of the erythrocyte-IC
clearing mechanism may be strongly influenced by the rate at
which antigen enters the circulation. For example, at any given
level of circulating antibody, if antigen is given as a large bolus,
the IC that form at the point of entry of antigen into the
circulation will form in antigen excess. By contrast, if the same
amount of antigen enters the circulation over a prolonged
period of time, the IC that form at the point of entry of antigen
into the circulation will form in antibody excess. IC that form in
antigen excess are smaller, activate complement less well and
bind less well to E-CR1, compared to IC that form nearer to
antibody excess [1, 2]. In addition, if the bolus represents a
large amount of antigen, the capacity of the E-CR1 system to
bind and clear the IC may be overwhelmed. By contrast, if the
same amount of antigen enters the circulation over a prolonged
period of time, the IC will form in antibody excess and in
amounts that can be more easily handled by the erythrocyte-IC
clearing mechanism [1, 2]. In short, the type of IC formed, its
dynamics in the circulation and its pathophysiologic effects may
be profoundly influenced by whether the given amount of
antigen enters the circulation over 10 minutes or over 24 hours.
Thus, in the primate, the bolus model of IC-ON may be
radically different pathophysiologically from a model in which
antigen enters the circulation over a prolonged period of time.
The present studies also call into question the relevance of
the daily bolus model of IC-GN to the pathogenesis of naturally
occurring IC-GN in humans. That is, the model of IC-ON
involving daily bolus infusion of antigen has clinical features
that bear little or no resemblance to IC-GN as it occurs
naturally in humans. The features of the bolus model of IC-GN
that have no obvious counterparts in human IC-GN are: daily
episodes of respiratory distress when the antigen is being
infused into the circulation, daily acute 30 to 50% reduction in
circulating leukocyte and platelet levels, daily precipitous 20 to
30% decreases in C3 levels, and daily transient decreases in
blood pressure as the antigen is being infused [11, 12]. The
absence of these acute phenomena in naturally occurring
IC-GN in humans suggests that, if formation and deposition of
circulating IC is important in the pathogenesis of IC-GN in
Table 3. Glomerular morphometry and related clinical data in the CYN subjected to the interventions to change E-CR1 levels while
undergoing GN induction with the bolus model of IC-GN
Glomerular deposits %
UiU' •Week&
Mean CR1/E"
Ab' BGGmName Sub epic Total cap5 Mesh
Before
PL
During
ON-P
Wia 0.0 0.2 11.7 1.7 14 740 910 27 3.3
Cab 0.2 3.0 5.4 0.8 10 910 1280 100 8.2
Eli' 0.9 0.9 18.3 0.5 10 950 1700 108 6.2
Vc' 0.8 1.2 24.0 0.6 10 560 1700 169 8.1
Nob 0.9 1.1 4.7 0.2 8 230 970 210 10.0
01b 2.5 4.8 16.1 2.0 8 360 610 202 11.67
Pa" 0.9 2.5 10.5 0.3 8 530 600 185 10.4
Irk' 6.8 14.9 20.8 0.4 8 1360 1800 60 4.8
To" 0.0 0.3 16.9 0,2 8 302 790 10 2.3
1.4±0.7 3.2± 1.5 14.3 0.7±0,2 9.3 660± 120 1150±160 119±25 7.2± 1.1
Unc 18.0 21.8 29,8 8.6 14 670 210 24 3.6
Dad 15.4 23.4 44.6 1.8 10 450 460 104 7.6
La" 3.7 5.1 17.6 0.3 8 580 490 140 10.0
Mad 0.5 0.5 5.6 0.2 8 640 560 190 10.0
Le" 9.7 14.6 29,4 1.5 8 520 560 134 10.0
Wi" 0.4 1.8 15.3 1.3 8 930 560 12 2.7
Du" 0.2 1.2 8.4 2.1 8 500 890 168 10.8
6.8±2.9 9.8±3.8 21.5±5.2 2.3±1.! 9.1±0.9 610±60 530±80 110±26 7.8±1.3
CYN with E-CR1 increased by exchange transfusion.
b CYN with E-CRI increased by phlebotomy.
CYN with E-CR1 decreased by exchange transfusion,
"CYN with E-CR1 maintained by sham PL.
Deposit expressed as % of capillary length or mesangial volume. No glomerular deposits were present in biopsies obtained prior to GN
induction protocol.
Glomerular capillary subepithelial.
5Total glomerular capillary wall deposits (% supepi + % subendothelial + % intramembranous).
"Mesangial.
'Urine protein, mg/dl/urine creatinine, mg/dl measured on the last day of the GN induction protocol.
Total duration of the GN-induction protocol.
k Mean CRIIE measured before and during the ON-induction protocol (GN-P). Shown are the average of all Monday and Thursday values for
each CYN.
'Mean precipitating antibody level (g BGG precipitated/mi of plasma) during GN-P.
Average daily mg BGG dose/kg body wt during GN-P.
See text for discussion of statistical analyses.
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humans, the antigen probably enters the circulation over pro-
longed periods of time, rather than as large boluses on repeated
occasions. If this is the case, the bolus method of providing
antigen is, itself, an artifact. This may be a crucial artifact when
considering the pathogenesis of IC-GN in the primate with its
erythrocyte-IC clearing mechanism, the function of which may
be very sensitive to the rate at which immune complexes form
in the circulation. Thus, although the bolus model of IC-GN is
the traditional means for inducing GN, multiple large bolus
entries of antigen into the circulation may not be relevant to the
way in which IC accumulates in glomeruli in human disease.
The PL/sham PL model [131 is an effective means to produce
large and sustained increases in mean CR1IE between the PL
and sham PL groups. The model is relatively easy to execute
and is well-tolerated by the CYN. The PL/sham PL model
should be useful in future studies examining the effects of
increased E-CR1 expression which may include effects on
immunoregulation, control of complement activation, as well as
effects to increase the clearance of IC from the circulation [1,
2]. Although decreased hematocrit itself may influence the
evolution of glomerular injury [17], the decrease in hematocrit
is transient in the PL animals and thus may not be a confound-
ing variable.
The present study does not suggest that increased E-CR1
levels influence immune regulation as has been previously been
suggested [1, 2, 18]. Those suggestions were based on the
observations that C3b-opsonized IC that were "processed" by
degradation of C3b sites on the immune complexes by factor I
with CR1 as cofactor, were able to bind to CR2 receptors on B
cells thereby influencing B-cell activation [1, 2, 18]. Although
we found no effect of increased E-CR1 levels on antibody
responses to BGG immunizations, it is possible that the lack of
effect of E-CR1 on antibody response in our studies was related
to the large antigen load (sufficient to induce IC-GN). If a
smaller antigen load had been given (presumably the more usual
circumstance involving immunization) an effect of E-CR1 on
immune regulation might have been observed. This interpreta-
tion is plausible because other studies have shown that com-
plement depletion (which abrogates CR1 processing of comple-
ment-opsonized IC) markedly decreases antibody response to
primary immunization when low-dose antigen is given, but not
when high-dose antigen is given [19].
In summary, the present study shows that increased E-CR1
levels do not provide statistically significant protection against
IC-GN in a model in which the antigen is infused daily as a large
bolus. However, the traditional bolus model of IC-GN may not
be a relevant test of the protective function of the E-CR1
system because bolus infusion of antigen may overwhelm the
erythrocyte-IC clearing mechanism.
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